Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours ยท Estimated delivery Sep 6 - Sep 11
perioperative management of glp-1 agonists Clinical practice recommendations for the peri-operative ๐https://t.co/GmNx3EpNrI Size:40 Servings Endocrine Research glp-1 obesity drug news
glp-1 obesity drug news today september 15 2025 2024 was a record year for trials and is already poised to take over glp-1 news september 30 2025 โ
Retatrutide, Amycretin, Survodutide, VK2735, and MariTide are among the most watched pipeline assets heading into 2026 because each represents a different answer to the same commercial question: what comes after Ozempic, Wegovy, Mounjaro, and Zepbound
Endocrine Research
Size:40 Servings
They found rates of invasive recurrence and metastatic disease were high in both groups, but people using GLP-1s had a 74% lower risk of invasive or metastatic cancer progression
